BACKGROUND: We have previously shown that miR-215 suppressed the expression of key targets such as thymidylate synthase (TS), dihydrofolate reductase, and denticleless protein homolog (DTL) in colon cancer. miR-215 is a tumor suppressor candidate due to the upregulation of p53 and p21 by targeting DTL. However, high levels of miR-215 conferred chemoresistance due to cell cycle arrest and reduced cell proliferation by suppressing DTL. In this study, the clinical significance of miR-215 was further investigated as a potential prognostic biomarker in colon cancer patients. METHODS: Total RNAs were extracted from 34 paired normal and colon (stage II and III) tumor specimens using the Trizol-based approach. The levels of miR-215 and a closely related miR-192 were quantified using quantitative real-time polymerase chain reaction (qRT-PCR) expression analysis. The expression of DTL mRNA and protein were quantified by real time qRT-PCR and immunohistochemistry. RESULTS: The expression levels of miR-192 (P = .0008) and miR-215 (P < .0001) were significantly decreased in colon tumors compared with normal tissues. DTL was significantly over-expressed and was inversely correlated with miR-215, further suggesting an in vivo physiologic relevance of miR-215 mediated DTL suppression. Kaplan-Meier survival analysis by Cox regression revealed that high levels of miR-215 expression (hazard ratio, 3.516; 95% confidence interval, 1.007-12.28, P = .025) are closely associated with poor patient's overall survival. Furthermore, an elevated expression of a miR-215 target protein DTL was detected in colon cancer tissues whereas no expression was present in normal tissues. CONCLUSION: miR-215 has a unique potential as a prognostic biomarker in stage II and III colon cancer.
BACKGROUND: We have previously shown that miR-215 suppressed the expression of key targets such as thymidylate synthase (TS), dihydrofolate reductase, and denticleless protein homolog (DTL) in colon cancer. miR-215 is a tumor suppressor candidate due to the upregulation of p53 and p21 by targeting DTL. However, high levels of miR-215 conferred chemoresistance due to cell cycle arrest and reduced cell proliferation by suppressing DTL. In this study, the clinical significance of miR-215 was further investigated as a potential prognostic biomarker in colon cancerpatients. METHODS: Total RNAs were extracted from 34 paired normal and colon (stage II and III) tumor specimens using the Trizol-based approach. The levels of miR-215 and a closely related miR-192 were quantified using quantitative real-time polymerase chain reaction (qRT-PCR) expression analysis. The expression of DTL mRNA and protein were quantified by real time qRT-PCR and immunohistochemistry. RESULTS: The expression levels of miR-192 (P = .0008) and miR-215 (P < .0001) were significantly decreased in colon tumors compared with normal tissues. DTL was significantly over-expressed and was inversely correlated with miR-215, further suggesting an in vivo physiologic relevance of miR-215 mediated DTL suppression. Kaplan-Meier survival analysis by Cox regression revealed that high levels of miR-215 expression (hazard ratio, 3.516; 95% confidence interval, 1.007-12.28, P = .025) are closely associated with poor patient's overall survival. Furthermore, an elevated expression of a miR-215 target protein DTL was detected in colon cancer tissues whereas no expression was present in normal tissues. CONCLUSION:miR-215 has a unique potential as a prognostic biomarker in stage II and III colon cancer.
Authors: E Chu; S M Copur; J Ju; T M Chen; S Khleif; D M Voeller; N Mizunuma; M Patel; G F Maley; F Maley; C J Allegra Journal: Mol Cell Biol Date: 1999-02 Impact factor: 4.272
Authors: Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond Journal: Nature Date: 2005-06-09 Impact factor: 49.962
Authors: Shayna L Showalter; Timothy N Showalter; Agnes Witkiewicz; Robert Havens; Eugene P Kennedy; Tomas Hucl; Scott E Kern; Charles J Yeo; Jonathan R Brody Journal: Cancer Biol Ther Date: 2008-04-21 Impact factor: 4.742
Authors: Yaguang Xi; Andrea Formentini; Minchen Chien; David B Weir; James J Russo; Jingyue Ju; Marko Kornmann; Jingfang Ju Journal: Biomark Insights Date: 2006
Authors: Mansi A Parasramka; W Mohaiza Dashwood; Rong Wang; Amir Abdelli; George S Bailey; David E Williams; Emily Ho; Roderick H Dashwood Journal: Mol Nutr Food Res Date: 2012-05-29 Impact factor: 5.914
Authors: Nicole Ludwig; Petra Leidinger; Kurt Becker; Christina Backes; Tobias Fehlmann; Christian Pallasch; Steffi Rheinheimer; Benjamin Meder; Cord Stähler; Eckart Meese; Andreas Keller Journal: Nucleic Acids Res Date: 2016-02-25 Impact factor: 16.971
Authors: William C Reinhold; Margot Sunshine; Hongfang Liu; Sudhir Varma; Kurt W Kohn; Joel Morris; James Doroshow; Yves Pommier Journal: Cancer Res Date: 2012-07-15 Impact factor: 12.701